FluoroPharma Medical, Massachusetts-based developer of advanced imaging pharmaceuticals for use with positron emission tomography (PET), intends to become the leader in the early detection of coronary artery and alzheimer diseases, two of the most high-profile diseases in the country. Through the use of unique FluoroPharma chemical agents, PET technology will help clinicians detect and assess subtle indications of pathology long before the appearance of traditional symptoms. Early detection has long been established as a major factor in the success of disease intervention, and is also a critical tool in associated research.
The technology behind such early detection is represented by FluoroPharma’s principal products:
• CardioPET – This imaging agent exploits the dietary needs of the heart as it relates to glucose and fatty acids. By introducing a chemical group which alters the breakdown of fatty acids (the hearts main food source), clinicians can track their distribution into the heart muscle and assess health and viability.
- Agent: Muscle State Imaging Agent
- Type: Fatty Acid (Labeled with Fluorine 18)
- Condition: Coronary Artery Disease
- Status: Phase 1 clinical trials completed
• BFPET – By recognizing the electrical charge of the myocardial cell walls, this imaging agent allows a view into the blood flow of the heart, and identifies tissue with perfusion as well as mitochondrial integrity of the cells – a strong indicator for cell viability.
- Agent: Blood Flow Imaging Agent
- Type: Positively Charged Molecule (Labeled with Fluorine 18)
- Condition: Coronary Artery Disease
- Status: Phase 1 clinical trials completed
• VasoPET – By targeting active molecule receptors associated with inflammatory conditions, this imaging agent allows visualization of areas in the blood vessels that may potentially initiate thrombosis and embolism.
- Agent: Vulnerable plaque Imaging Agent
- Type: Receptor Connecting Molecule (Labeled with Fluorine 18)
- Condition: Coronary Artery Disease
- Status: Pre-Clinical studies completed
• AZPET – This imaging agent specifically seeks out and attaches to amyloid deposits in the brain. This allows a PET scan to reveal the areas where amyloid plaque has deposited, helping in the early detection of Alzheimer’s disease.
- Agent: Amyloid Deposit Imaging Agent
- Type: Molecule that targets that bind Amyloid Protein (Labeled with Fluorine 18)
- Condition: Alzheimer’s Disease
- Status: Development Stage
For more information, see the company website at www.FluoroPharma.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
